According to an article in Health Day News (November 19, 2010) at the request of the U.S. Food and Drug Administration, Xanodyne pharmaceuticals have agreed to withdraw Propoxyphene, an opiate used to treat mild to moderate pain, from the U.S. market due to the risk of potentially serious or even fatal heart rhythm heart abnormalities. This drug is sold by prescription as a single agent (Darvon) or in combination with Acetaminophen (Darvocet). Apparently the FDA recently sought to request withdraw of Propoxyphene from the market, as the agency concluded that the risk of Propoxyphene out weighed the benefits of the drug. According to the article new clinical data presented to the FDA revealed the potential of heart rhythm abnormalities related to the drug.
For more information on Products Liability Click Here: http://www.brevardlawyer.com/html/preise.html